EMA to developers: Drop inhalers on the ground; Bend teams with Catalent for controlled-release tech;

 @DamianFierce: Researchers say a reusable ultrasound pill could replace daily injections for patients with cancer and diabetes. Report | Follow @DamianFierce

> The EMA has an interesting request for makers of drug-delivering inhalers: drop them on the ground. The European regulator wants manufacturers to be sure their techs can withstand the normal wear-and-tear of patient use, which includes accidental drops. More

> Medgenics ($MDGN) has received an Orphan Drug Designation from the FDA for Infradure, its hepatitis D treatment that uses the company's innovative Biopump delivery platform. News

> The CEO and co-founder of drug delivery firm BIND Biosciences received the Ernst & Young New England Entrepreneur of the Year Award. The company, founded by MIT's Robert Langer, is developing targeted, programmable cancer treatments. Item

> Bend Research is partnering with Catalent Pharma Solutions, looking to offer controlled-release drug delivery solutions to developers. Release

Suggested Articles

Rutgers scientists have developed an anti-inflammatory drug delivery platform to better treat central nervous system injuries and disease.

Purdue's reformulated OxyContin may stop patients from snorting or injecting the drug, but it doesn't curb abuse overall, an FDA panel determined.

Roche is gearing up to launch an eye implant to make its Lucentis AMD drug easier to use. But the drugmaker has even bigger plans for the device.